• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.

作者信息

Schachat Andrew P

出版信息

Am J Ophthalmol. 2013 Jul;156(1):1-2.e1. doi: 10.1016/j.ajo.2013.04.009.

DOI:10.1016/j.ajo.2013.04.009
PMID:23791369
Abstract
摘要

相似文献

1
Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.转换抗血管内皮生长因子疗法治疗新生血管性年龄相关性黄斑变性。
Am J Ophthalmol. 2013 Jul;156(1):1-2.e1. doi: 10.1016/j.ajo.2013.04.009.
2
Current concepts in managing wet AMD suboptimally responsive to anti-VEGF therapy.抗VEGF治疗反应欠佳的湿性年龄相关性黄斑变性的当前管理理念
Ophthalmic Surg Lasers Imaging Retina. 2013 May-Jun;44(3):225-6. doi: 10.3928/23258160-20130503-01.
3
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.阿柏西普治疗对贝伐单抗和雷珠单抗抵抗的渗出性年龄相关性黄斑变性。
Am J Ophthalmol. 2013 Jul;156(1):15-22.e1. doi: 10.1016/j.ajo.2013.02.017. Epub 2013 May 22.
4
[Anti-VEGF therapy of neovascular age-related macular degeneration: therapeutic strategies status December 2012].[新生血管性年龄相关性黄斑变性的抗血管内皮生长因子治疗：2012年12月治疗策略现状]
Klin Monbl Augenheilkd. 2013 Feb;230(2):170-7. doi: 10.1055/s-0032-1328113. Epub 2013 Feb 21.
5
Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.将慢性难治性或复发性新生血管性年龄相关性黄斑变性转为使用阿柏西普治疗。
Am J Ophthalmol. 2013 Jul;156(1):29-35.e2. doi: 10.1016/j.ajo.2013.03.030. Epub 2013 May 10.
6
[Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab].阿柏西普治疗对雷珠单抗和/或贝伐单抗耐药的湿性年龄相关性黄斑变性患者的初步经验
Arch Soc Esp Oftalmol. 2014 Jan;89(1):42-3. doi: 10.1016/j.oftal.2013.05.002. Epub 2013 Aug 7.
7
Aflibercept anti-vascular endothelial growth factor therapy in vitrectomized eyes with neovascular age-related macular degeneration.阿柏西普抗血管内皮生长因子疗法用于玻璃体切除术后的新生血管性年龄相关性黄斑变性患者。
Acta Ophthalmol. 2016 May;94(3):e249-50. doi: 10.1111/aos.12840. Epub 2015 Sep 24.
8
Initial improvements when converting eyes with treatment-resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks.当将治疗抵抗性渗出性年龄相关性黄斑变性的眼睛转换为阿柏西普治疗时，最初的改善在将治疗间隔从4周增加到8周后会大幅减少。
Acta Ophthalmol. 2015 Sep;93(6):e510-1. doi: 10.1111/aos.12681. Epub 2015 Feb 23.
9
Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments.新生血管性年龄相关性黄斑变性：抗血管生成治疗时代的个体化治疗。
Ophthalmology. 2013 May;120(5 Suppl):S23-5. doi: 10.1016/j.ophtha.2013.01.059.
10
Retinal pigment epithelial tear after intravitreal aflibercept for neovascular age-related macular degeneration.玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性后发生的视网膜色素上皮撕裂
Ophthalmic Surg Lasers Imaging Retina. 2015 Jan;46(1):87-90. doi: 10.3928/23258160-20150101-16.

引用本文的文献

1
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration.优化新生血管性年龄相关性黄斑变性患者治疗效果的治疗方案。
Eye (Lond). 2025 Apr;39(5):860-869. doi: 10.1038/s41433-024-03370-0. Epub 2024 Oct 8.
2
Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes.切换至 aflibercept（3mg）治疗治疗抵抗性湿性年龄相关性黄斑变性：1 年结果。
Medicine (Baltimore). 2024 Apr 19;103(16):e37839. doi: 10.1097/MD.0000000000037839.
3
Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry.
治疗新生血管性年龄相关性黄斑变性：来自柏林黄斑登记处的药物转换真实世界的见解。
Graefes Arch Clin Exp Ophthalmol. 2023 Jun;261(6):1681-1690. doi: 10.1007/s00417-022-05952-8. Epub 2023 Jan 12.
4
A biocompatible reverse thermoresponsive polymer for ocular drug delivery.一种用于眼部药物输送的生物相容的反向温敏聚合物。
Drug Deliv. 2019 Dec;26(1):343-353. doi: 10.1080/10717544.2019.1587042.
5
Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance.雷珠单抗治疗史作为阿柏西普转换反应的预测指标：药物耐受性的证据。
Clin Ophthalmol. 2018 Mar 28;12:593-600. doi: 10.2147/OPTH.S160367. eCollection 2018.
6
"What should I inject next?" Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD.“接下来我应该注射什么？”多种抗血管内皮生长因子治疗中具有挑战性的治疗决策：关于探索湿性年龄相关性黄斑变性抗血管内皮生长因子转换的出版物综述
Int Ophthalmol. 2018 Oct;38(5):2031-2039. doi: 10.1007/s10792-017-0695-z. Epub 2017 Aug 29.
7
HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.高剂量高频阿柏西普治疗难治性新生血管年龄相关性黄斑变性。
Retina. 2018 Jun;38(6):1156-1165. doi: 10.1097/IAE.0000000000001726.
8
Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy.光动力疗法、阿柏西普和地塞米松三联疗法治疗息肉状脉络膜血管病变。
Sci Rep. 2016 Nov 16;6:36870. doi: 10.1038/srep36870.
9
Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.阿柏西普对雷珠单抗和贝伐单抗治疗无效患者视力及黄斑中心厚度的短期影响
Wien Klin Wochenschr. 2017 May;129(9-10):351-357. doi: 10.1007/s00508-016-1055-0. Epub 2016 Aug 22.
10
Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration.阿柏西普：用于治疗年龄相关性黄斑变性所致脉络膜新生血管的综述
Clin Ophthalmol. 2015 Dec 17;9:2355-71. doi: 10.2147/OPTH.S80040. eCollection 2015.